Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
Acknowledgements This work was supported by the National Institute for Diabetes and Digestive and Kidney Diseases (F30 award DK117570, T32 award DK108735-01)
Bharti, J., Sonthalia, S., & Jakhar, D
The Takeaway GLP1 drugs like semaglutide and liraglutide have reshaped diabetes and obesity treatment, and theyre now generating excitement in Alzheimers research
The most frequently reported adverse events (AEs) of GLP-1 RAs were gastrointestinal adverse drug reactions, including nausea, vomiting, and abdominal pain, which were closely related to activation of central and peripheral GLP-1 receptors ( In a recent network meta-analysis, overall GLP-1 RAs significantly increased the incidence of gastrointestinal AEs compared with placebo or conventional treatment, and the odds ratios for nausea, vomiting and diarrhea from GLP-1 RAs were 11.8 (95% CI, 2.8946.9), 51.7 (95% CI, 7.07415), and 4.93 (95% CI, 1.7514.7), respectively ( Methods Data sources This retrospective pharmacovigilance study was conducted based on the FDA Adverse Event Reporting System (FAERS) database
Cole, M
US$ 26.59
US$ 20.59
US$ 21.07
